Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-047008
Filing Date
2023-09-07
Accepted
2023-09-07 16:18:40
Documents
47
Period of Report
2023-07-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-20230731.htm   iXBRL 10-Q 1390058
2 EX-31.1 kalv-ex31_1.htm EX-31.1 21869
3 EX-31.2 kalv-ex31_2.htm EX-31.2 19706
4 EX-32.1 kalv-ex32_1.htm EX-32.1 14531
  Complete submission text file 0000950170-23-047008.txt   4842038

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kalv-20230731_cal.xml EX-101.CAL 44050
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kalv-20230731_def.xml EX-101.DEF 60607
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kalv-20230731.xsd EX-101.SCH 27394
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kalv-20230731_lab.xml EX-101.LAB 244954
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kalv-20230731_pre.xml EX-101.PRE 164999
41 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20230731_htm.xml XML 875145
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 231242492
SIC: 2834 Pharmaceutical Preparations